9 days ago
LLY
AnalystsChris SchottChris Schott's Stock Forecasts
AnalystsChris Schott
Analyst Ranking
Top 22%
#1065 out of 4981 analysts
Average Return
+5.26%
Win Rate
56%38 out of 68
Risk vs Reward
Poor
Good
Chris Schott's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +85.30% | $395.86 | $733.51 | 2023-04-28 - 2024-04-26 | Strong Buy |
Eli Lilly & CoLLY | +75.50% | $458.48 | $804.62 | 2023-07-28 - 2024-07-26 | Strong Buy |
Kala Bio IncKALA | +73.24% | $205.50 | $356.00 | 2019-11-08 - 2020-11-06 | Strong Buy |
Eli Lilly & CoLLY | +71.55% | $428.44 | $734.97 | 2023-05-04 - 2024-05-03 | Strong Buy |
Heska CorpHSKA | +66.51% | $72.06 | $119.99 | 2022-10-17 - 2023-06-12 | Strong Buy |
Chris Schott Analyst Color
Get additional color on Chris Schott's coverage of popular stocks
12 days ago
IDXX
3 months ago
TEVA
6 months ago
AMRX
a year ago
LLY
a year ago
LLY
a year ago
LLY
2 years ago
PFE
2 years ago
LLY
2 years ago
LLY
2 years ago
LLY
2 years ago
LLY
Chris Schott's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 13 | Strong Buy | $1,100.00 | +56.87% | Reiterates | 9 days ago |
Perrigo Co PLCPRGO | 5 | Strong Buy | $35.00 | +54.19% | Maintains | 9 days ago |
Idexx Laboratories IncIDXX | 8 | Strong Buy | $675.00 | +3.71% | Maintains | 12 days ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $800.00 | +37.83% | Maintains | 2 months ago |
Teva Pharmaceutical Industries LtdTEVA | 6 | Strong Buy | $23.00 | +28.78% | Upgrades | 3 months ago |
Biogen IncBIIB | 4 | Hold | $175.00 | +26.26% | Maintains | 3 months ago |
Gilead Sciences IncGILD | 6 | Strong Buy | $130.00 | +9.83% | Maintains | 5 months ago |
Amneal Pharmaceuticals IncAMRX | 2 | Strong Buy | $12.00 | +26.98% | Upgrades | 6 months ago |
Abbvie IncABBV | 2 | Strong Buy | $200.00 | -3.24% | Maintains | 9 months ago |
Zoetis IncZTS | 2 | Strong Buy | $230.00 | +49.24% | Maintains | 10 months ago |
Organon & CoOGN | 2 | Strong Sell | $20.00 | +111.86% | Downgrades | a year ago |
Royalty Pharma PLCRPRX | 4 | Strong Buy | $42.00 | N/A | Maintains | a year ago |
Amgen IncAMGN | 1 | Hold | $270.00 | N/A | Reinstates | 2 years ago |
Pfizer IncPFE | 3 | Hold | $34.00 | N/A | Maintains | 2 years ago |
Merck & Co IncMRK | 4 | Strong Buy | $125.00 | N/A | Maintains | 2 years ago |
Viatris IncVTRS | 2 | Hold | $14.00 | N/A | Maintains | 3 years ago |
Coherus Biosciences IncCHRS | 2 | Hold | $11.00 | N/A | Maintains | 3 years ago |
Eqrx IncEQRX | 2 | Strong Sell | N/A | N/A | Downgrades | 3 years ago |
Elanco Animal Health IncELAN | 3 | Hold | $20.00 | N/A | Maintains | 3 years ago |
Heska CorpHSKA | 2 | Strong Buy | $150.00 | N/A | Maintains | 3 years ago |
Bausch Health Companies IncBHC | 3 | Hold | N/A | N/A | Downgrades | 3 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 1 | Strong Buy | $110.00 | N/A | Initiates Coverage On | 5 years ago |
Kala Bio IncKALA | 4 | Strong Buy | $950.00 | N/A | Maintains | 5 years ago |
Endo International PLCENDPQ | 2 | Hold | $10.00 | N/A | Maintains | 6 years ago |
Pacira Biosciences IncPCRX | 2 | Hold | $50.00 | N/A | Maintains | 7 years ago |
Bristol Myers Squibb CoBMY | 1 | Strong Buy | $74.00 | N/A | Maintains | 7 years ago |
Therapeuticsmd IncTXMD | 1 | Strong Buy | $550.00 | N/A | Initiates Coverage On | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.